The role of competitive binding to human serum albumin on efavirenz-warfarin interaction: a nuclear magnetic resonance study.
Int J Antimicrob Agents
; 42(5): 443-6, 2013 Nov.
Article
em En
| MEDLINE
| ID: mdl-24051055
ABSTRACT
The potential for co-prescription of the anti-human immunodeficiency virus (anti-HIV) drug efavirenz (EFV) and the oral anticoagulant warfarin (WAR) is currently high as EFV is a drug of choice for HIV type 1 infection and because cardiovascular disease is increasing among HIV-infected individuals. However, clinical reports of EFV-WAR interaction, leading to WAR overdosing, call for elucidation of the mechanisms involved in this drug-drug interaction. Here we present the first report demonstrating competition of the two drugs for the same binding site of human serum albumin. Using ligand-based nuclear magnetic resonance experiments, this study proves that EFV has an effect on the concentration of free WAR. This previously unidentified EFV-WAR interaction represents a potential risk factor that should be taken into account when considering treatment options.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Varfarina
/
Albumina Sérica
/
Fármacos Anti-HIV
/
Benzoxazinas
/
Anticoagulantes
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article